Neurogene Inc.
NGNE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $925 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $3,247 | $3,262 | $3,196 | $42,264 |
| Gross Profit | -$2,322 | -$3,262 | -$3,196 | -$42,264 |
| % Margin | -251% | – | – | – |
| R&D Expenses | $60,917 | $44,394 | $47,505 | $42,264 |
| G&A Expenses | $22,613 | $11,189 | $9,012 | $8,270 |
| SG&A Expenses | $22,613 | $11,189 | $9,012 | $8,270 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$3,247 | -$3,262 | -$3,196 | -$42,264 |
| Operating Expenses | $80,283 | $52,321 | $53,321 | $8,270 |
| Operating Income | -$82,605 | -$55,583 | -$56,517 | -$50,534 |
| % Margin | -8,930.3% | – | – | – |
| Other Income/Exp. Net | $7,461 | $19,266 | $1,328 | $17 |
| Pre-Tax Income | -$75,144 | -$36,317 | -$55,189 | -$50,517 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$75,144 | -$36,317 | -$55,189 | -$50,517 |
| % Margin | -8,123.7% | – | – | – |
| EPS | -4.28 | -2.83 | -4.3 | -0.92 |
| % Growth | -51.2% | 34.2% | -367.4% | – |
| EPS Diluted | -4.28 | -2.83 | -4.3 | -0.92 |
| Weighted Avg Shares Out | 17,567 | 12,824 | 12,824 | 55,042 |
| Weighted Avg Shares Out Dil | 17,567 | 12,824 | 12,824 | 55,042 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8,467 | $2,951 | $1,337 | $19 |
| Interest Expense | $12 | $12 | $2 | $0 |
| Depreciation & Amortization | $3,247 | $3,297 | $3,196 | $947 |
| EBITDA | -$71,885 | -$52,286 | -$51,991 | -$49,587 |
| % Margin | -7,771.4% | – | – | – |